Improving Clinical Outcomes in the
Treatment and Management of PAH

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from April 30, 2018 to April 30, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Actelion Pharmaceuticals US Inc.

Pulmonary Arterial Hypertension (PAH) is a progressive vascular disorder and though relatively rare, PAH is a very serious, life threatening condition that worsens over time and for which there is no cure. Over time, the heart muscle can become so weakened that its ability to pump enough blood through the body is lost, leading to heart failure – the most common cause of death for PAH patients. Approximately half of people diagnosed with PAH will not live past five years, while those with untreated PAH have an average survival expectancy of approximately three years following diagnosis. Additionally, PAH often leads to the onset of co-morbidities associated with the disease, which not only puts the patient at higher risk but also increases the costs to the healthcare system. Early diagnosis and accurate classification are keys to managing costs. Thankfully advancements in diagnostic criteria, guidelines, classifications and emerging treatments continue to be updated to find the best treatment for the severity and individual nature of the disease in each patient. There are several treatments for PAH depending on the severity and the patient’s profile. These include monotherapy and combination therapies that can include prostacyclin/prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors.

Upon Completion of this activity, participants will be able to:

  • Identify the recently published evidence-based treatment guidelines for appropriate management of PAH

  • Explore the PAH risk factors and clinical classifications for conducting a more accurate diagnosis

  • Analyze the strategies to optimize therapy in patients with PAH as well as the underlying comorbidities associated with the disease

  • Assess new clinical data on treatment approaches for patients not meeting the treatment goals with the first line of therapy

  • Discuss effective therapeutic strategies including sequential combination therapy in patients with PAH

Faculty: Charles Burger, MD
Professor of Medicine
Mayo Clinic College of Medicine


Dr. Burger serves on an advisory board for Actelion Pharmaceuticals and Gilead Sciences. He also receives research support from Actelion Pharmaceuticals, Bayer, Gilead Sciences and United Therapeutics. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Actelion Pharmaceuticals US Inc.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue